Teaching Staff
HONG, Yanjun - Research Assistant Professor

Educational Background
  • B.Sc., Zhejiang University, China
  • Ph.D., Zhejiang University, China
  • Postdoctoral: National University of Singapore, Singapore

Current Research Interests
  • Metabonomics: Mass spectrometry-based metabolic phenotyping of human disease to identify biomarkers and understand the underlying pathologies
  • Drug metabolism: Application of pharmacological and bioanalytical approaches to address research questions in drug metabolism, inhibition and drug-drug interactions.


Selected Publications
  1. Y. J. Hong, Y. M. F. Chia, R. H. Yeo, G. Venkatesan, S. K. Koh, C. L. L. Chai, L. Zhou, P. Kojodjojo and E. C. Y. Chan, “Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-desbutyl Dronedarone”, Mol. Pharmacol, 89(1), 1-13 (2015).
  2. Y. J. Hong, K. Esuvaranathan, K. K. Pasikanti, E. C. Y. Chan, “Metabonomic Diagnosis of Bladder Cancer - What are the Advantages and Considerations?”, Bioanalysis, 7(21), 2727-2729 (2015).
  3. T. P. Lim, Y. Cai, Y. J. Hong, E. C. Y. Chan and et. al., “In-vitro Pharmacodynamics of Various Antibiotics in Combination Against Extensively Drug-resistant Klebsiella Pneumoniae”, Antimicrob. Agents Chemother., 59(5), 2515-2524 (2015).
  4. E. C. Y. Chan, K. K. Pasikanti, Y.  Hong, P. Ho and et.al., “Metabonomic Profiling of Bladder Cancer”, J. Proteome Res., 14(2), 587-602 (2014).
  5. P. Bahety, Y. M. Tan, Y. J. Hong, L. Zhang, E. C. Y. Chan, P. L. R. Ee, “Metabotyping of Docosahexaenoic Acid-treated Alzheimer’s Disease Cell Model”, PloS one., 9, e90123 (2014).
  6. K. K. Pasikanti, K. Esuvaranathan, Y. J. Hong, P. C. Ho, R. Mahendran, N. M. L. Raman, E. C. Y. Chan., “Urinary Metabotyping of Bladder Cancer Using Two-dimensional Gas Chromatography Time-of-flight Mass Spectrometry”, J. Proteome Res., 12(9), 3865-3873 (2013).
  7. T. Liu, Y. J. Hong, P. Huang, Z. H. Li, J. Y. Hong, S. Zeng, M. Y. Zheng, S. Q. Chen, “An Investigation of the Catalytic Activity of CYP2A134 with Coumarin and Polymorphisms of CYP2A13 in a Chinese Han Population”, Drug Metab. Dispos. 40(5), 847-851(2012).
  8. L. S. Yu, Y. J. Hong, L. Li, Y. X. Jin, M. Y. Zheng, H. L. Jiang, S. Zeng, “Enantioselective Drug-protein Interaction between Mexiletine and Plasma Protein”, J. Pharm. Pharmacol., 64(6), 792-801 (2012).
  9. Y. J. Hong, Y. H. Tang, S. Zeng. “Enantioselective Plasma Protein Binding of Propafenone: Mechanism, Drug Interaction, and Species Difference”, Chirality, 1, 692–698 (2009).
  10. Y. J. Hong, X. D. Wang, D. Shen, S. Zen, “Discrimination Analysis of Mass Spectrometry Proteomics for Ovarian Cancer Detection”, Acta Pharmacol. Sin., 29, 1240-1246 (2008).